REGENXBIO Inc. cotiza a 7.77 USD y tiene una capitalización bursátil de $513M. En los últimos 12 meses ha facturado $174M con un margen de flujo de caja libre del -74.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.43 | $-1.72 | $-1.30 |
| Estimado | $-1.30 | $-0.11 | $-1.41 | $-0.84 |
| Sorpresa | — | +490.9% | -22.0% | -54.8% |
| Métrica | RGNX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -94.6% | -38.6% | -56.0% |
| Net Margin | -113.8% | -33.6% | -80.2% |
| FCF Margin | -74.2% | -13.9% | -60.3% |
| ROE | -188.7% | -40.4% | -148.3% |
| ROA | -42.8% | -32.0% | -10.8% |
| Current Ratio | 2.38 | 2.84 | -0.46 |
| Debt / Equity | — | 0.28 | — |